RU2017141447A - Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 - Google Patents
Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 Download PDFInfo
- Publication number
- RU2017141447A RU2017141447A RU2017141447A RU2017141447A RU2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A
- Authority
- RU
- Russia
- Prior art keywords
- influenza virus
- virus
- polypeptide
- vlp
- immune response
- Prior art date
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims 25
- 229920001184 polypeptide Polymers 0.000 title claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 13
- 239000000203 mixture Substances 0.000 title claims 8
- 230000028993 immune response Effects 0.000 title claims 7
- 238000000034 method Methods 0.000 title claims 7
- 206010069767 H1N1 influenza Diseases 0.000 title claims 6
- 201000010740 swine influenza Diseases 0.000 title claims 6
- 241000700605 Viruses Species 0.000 title 1
- 206010022000 influenza Diseases 0.000 title 1
- 101710154606 Hemagglutinin Proteins 0.000 claims 14
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 14
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 14
- 101710176177 Protein A56 Proteins 0.000 claims 14
- 239000000185 hemagglutinin Substances 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102000005348 Neuraminidase Human genes 0.000 claims 4
- 108010006232 Neuraminidase Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 108060003393 Granulin Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617815P | 2012-03-30 | 2012-03-30 | |
| US61/617,815 | 2012-03-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014142785A Division RU2639551C2 (ru) | 2012-03-30 | 2013-03-12 | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017141447A true RU2017141447A (ru) | 2019-02-13 |
Family
ID=49261015
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017141447A RU2017141447A (ru) | 2012-03-30 | 2013-03-12 | Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 |
| RU2014142785A RU2639551C2 (ru) | 2012-03-30 | 2013-03-12 | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014142785A RU2639551C2 (ru) | 2012-03-30 | 2013-03-12 | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9212207B2 (enExample) |
| EP (1) | EP2831094B1 (enExample) |
| JP (1) | JP2015513902A (enExample) |
| KR (1) | KR20150004800A (enExample) |
| CN (1) | CN104395336B (enExample) |
| AU (1) | AU2013240365B2 (enExample) |
| BR (1) | BR112014023900A2 (enExample) |
| CA (1) | CA2868330A1 (enExample) |
| HK (1) | HK1203522A1 (enExample) |
| IN (1) | IN2014DN07399A (enExample) |
| MX (1) | MX345150B (enExample) |
| MY (1) | MY166953A (enExample) |
| RU (2) | RU2017141447A (enExample) |
| SG (1) | SG11201406153XA (enExample) |
| WO (1) | WO2013148164A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2834969C1 (ru) * | 2020-05-08 | 2025-02-19 | Академиа Синика | Химерные вакцины против гриппа |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883171B2 (en) * | 2010-09-14 | 2014-11-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| EP2721158B1 (en) | 2011-06-20 | 2017-05-03 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for h1n1 influenza |
| MX2015005056A (es) * | 2012-11-27 | 2015-07-23 | Univ Pittsburgh | Antigenos ampliamente reactivos computacionalmente optimizados para influenza h1n1. |
| US20140286981A1 (en) | 2013-03-14 | 2014-09-25 | Wisconsin Alumni Research Foundation | Broadly reactive mosaic peptide for influenza vaccine |
| CA2970163A1 (en) * | 2014-12-19 | 2016-06-23 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| WO2016100922A1 (en) * | 2014-12-19 | 2016-06-23 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza |
| US10584148B2 (en) * | 2015-06-02 | 2020-03-10 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| CN108290932A (zh) * | 2015-06-09 | 2018-07-17 | 圣诺菲·帕斯图尔公司 | 优化编码工程改造的流感蛋白的核苷酸序列的方法 |
| US20200237898A1 (en) * | 2015-09-21 | 2020-07-30 | Oregon Health & Science University | Vaccines intelligently produced by epitope recombination (viper) for influenza |
| EP3464328A1 (en) * | 2016-06-02 | 2019-04-10 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| US11116832B2 (en) | 2016-06-03 | 2021-09-14 | Sanofi Pasteur Inc. | Modification of engineered influenza hemagglutinin polypeptides |
| CN112189019B (zh) * | 2018-03-28 | 2024-10-25 | 圣诺菲·帕斯图尔公司 | 产生包含血凝素的广泛保护性疫苗组合物的方法 |
| WO2019191261A1 (en) * | 2018-03-28 | 2019-10-03 | Sanofi Pasteur Inc. | Methods of generating broadly protective vaccine compositions comprising neuraminidase |
| CN112512565A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性流感-铁蛋白多肽 |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| JP7337921B2 (ja) * | 2018-11-06 | 2023-09-04 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 鳥インフルエンザウイルスｈ５亜型に対する免疫原性組成物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE376059T1 (de) | 2000-06-23 | 2007-11-15 | Wyeth Corp | Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps) |
| US20050181459A1 (en) | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| EP1851238A4 (en) | 2005-02-24 | 2008-12-31 | Univ Massachusetts | FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF |
| WO2007011904A2 (en) | 2005-07-19 | 2007-01-25 | Dow Global Technologies Inc. | Recombinant flu vaccines |
| WO2007072214A2 (en) | 2005-12-19 | 2007-06-28 | Novartis Vaccines And Diagnostics Srl | Methods of clustering gene and protein sequences |
| US20080045472A1 (en) | 2006-03-31 | 2008-02-21 | Council Of Scientific And Industrial Research Bharat Biotech | Targets for human micro rnas in avian influenza virus (h5n1) genome |
| HRP20130163T1 (hr) | 2006-09-07 | 2013-03-31 | Crucell Holland B.V. | Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba |
| TWI403518B (zh) * | 2007-01-23 | 2013-08-01 | Academia Sinica | 一種流感疫苗及其使用方法 |
| US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
| AU2008331673B2 (en) * | 2007-11-12 | 2014-12-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
| SG187500A1 (en) | 2008-01-21 | 2013-02-28 | Medicago Inc | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
| US7981428B2 (en) * | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
| WO2010036970A2 (en) | 2008-09-25 | 2010-04-01 | Fraunhofer Usa, Inc. | Influenza vaccines, antigens, compositions, and methods |
| WO2010036948A2 (en) | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
| KR101715418B1 (ko) | 2009-04-03 | 2017-03-10 | 메리얼 인코포레이티드 | 뉴캐슬 질환 바이러스-벡터를 이용한 조류 백신 |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| US8883171B2 (en) | 2010-09-14 | 2014-11-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| EP2721158B1 (en) | 2011-06-20 | 2017-05-03 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for h1n1 influenza |
| AU2013217166B2 (en) * | 2012-02-07 | 2017-04-06 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses |
| US9566327B2 (en) | 2012-02-13 | 2017-02-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for human and avian H5N1 influenza |
| MX2015005056A (es) | 2012-11-27 | 2015-07-23 | Univ Pittsburgh | Antigenos ampliamente reactivos computacionalmente optimizados para influenza h1n1. |
-
2013
- 2013-03-12 IN IN7399DEN2014 patent/IN2014DN07399A/en unknown
- 2013-03-12 RU RU2017141447A patent/RU2017141447A/ru not_active Application Discontinuation
- 2013-03-12 MY MYPI2014002785A patent/MY166953A/en unknown
- 2013-03-12 CA CA2868330A patent/CA2868330A1/en not_active Abandoned
- 2013-03-12 JP JP2015503258A patent/JP2015513902A/ja active Pending
- 2013-03-12 EP EP13769077.2A patent/EP2831094B1/en not_active Not-in-force
- 2013-03-12 MX MX2014011387A patent/MX345150B/es active IP Right Grant
- 2013-03-12 WO PCT/US2013/030530 patent/WO2013148164A1/en not_active Ceased
- 2013-03-12 US US14/388,726 patent/US9212207B2/en active Active
- 2013-03-12 BR BR112014023900-2A patent/BR112014023900A2/pt not_active IP Right Cessation
- 2013-03-12 AU AU2013240365A patent/AU2013240365B2/en not_active Ceased
- 2013-03-12 CN CN201380027311.0A patent/CN104395336B/zh not_active Expired - Fee Related
- 2013-03-12 HK HK15104016.5A patent/HK1203522A1/xx unknown
- 2013-03-12 KR KR1020147027594A patent/KR20150004800A/ko not_active Withdrawn
- 2013-03-12 SG SG11201406153XA patent/SG11201406153XA/en unknown
- 2013-03-12 RU RU2014142785A patent/RU2639551C2/ru not_active IP Right Cessation
-
2015
- 2015-11-12 US US14/939,279 patent/US9555095B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2834969C1 (ru) * | 2020-05-08 | 2025-02-19 | Академиа Синика | Химерные вакцины против гриппа |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1203522A1 (en) | 2015-10-30 |
| EP2831094B1 (en) | 2018-06-13 |
| US20150017196A1 (en) | 2015-01-15 |
| EP2831094A1 (en) | 2015-02-04 |
| CN104395336A (zh) | 2015-03-04 |
| EP2831094A4 (en) | 2015-10-14 |
| MX345150B (es) | 2017-01-18 |
| WO2013148164A1 (en) | 2013-10-03 |
| AU2013240365B2 (en) | 2017-03-30 |
| US9555095B2 (en) | 2017-01-31 |
| JP2015513902A (ja) | 2015-05-18 |
| MY166953A (en) | 2018-07-25 |
| RU2014142785A (ru) | 2016-05-20 |
| BR112014023900A2 (pt) | 2020-11-24 |
| CN104395336B (zh) | 2018-01-23 |
| US20160279226A1 (en) | 2016-09-29 |
| US9212207B2 (en) | 2015-12-15 |
| AU2013240365A1 (en) | 2014-10-23 |
| SG11201406153XA (en) | 2014-10-30 |
| IN2014DN07399A (enExample) | 2015-04-24 |
| RU2639551C2 (ru) | 2017-12-21 |
| MX2014011387A (es) | 2014-10-14 |
| KR20150004800A (ko) | 2015-01-13 |
| CA2868330A1 (en) | 2013-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017141447A (ru) | Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 | |
| RU2014101401A (ru) | Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств | |
| RU2018113521A (ru) | Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b | |
| JP7250878B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2015506705A5 (enExample) | ||
| CN105188745B (zh) | 稳定化的可溶性融合前rsv f多肽 | |
| JP6679475B2 (ja) | 安定化された可溶性融合前ｒｓｖ ｆポリペプチド | |
| AU2021232702B2 (en) | Stabilized pre-fusion RSV F proteins | |
| EP3821906A1 (en) | Vaccine against rsv comprising modified f polypeptide | |
| RU2015124805A (ru) | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1 | |
| RS61456B1 (sr) | Stabilizovani rastvorljivi pre-fuzioni rsv f protein za primenu u profilaksi rsv infekcije | |
| JP2016505538A5 (enExample) | ||
| WO2017207477A1 (en) | Stabilized pre-fusion rsv f proteins | |
| US9896484B2 (en) | Influenza virus recombinant proteins | |
| WO2013066365A1 (en) | Immunologic constructs and methods | |
| CN101899461A (zh) | 一种编码甲型流感病毒NP蛋白和M2e多肽的融合基因 | |
| CN115850395A (zh) | 一种流感病毒通用型纳米颗粒疫苗及其制备方法 | |
| WO2024199469A1 (zh) | 具有稳定融合前构象的呼吸道合胞病毒f蛋白 | |
| CA3213403A1 (en) | Modified chimeric coronavirus spike protein for enhancement of viral titers | |
| CN109821014A (zh) | 一种多抗原仿生流感疫苗及其制备方法和应用 | |
| OA19273A (en) | Stabilized pre-fusion RSV F proteins. | |
| HK40000138A (en) | Stabilized pre-fusion rsv f proteins | |
| OA17598A (en) | Stabilized soluble pre-fusion RSV F polypeptides | |
| OA17539A (en) | Stabilized soluble prefusion RSV F polypeptides. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20201130 |